CoChat

Association of APOE Genotype With Heterogeneity of Cognitive Decline Rate in Alzheimer Disease

Open access
Qian, Jing, Betensky, Rebecca A., Hyman, Bradley T., Serrano-Pozo, Alberto · 2021 · Neurology

The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.

Abstract

OBJECTIVE: genotype is a significant driver of heterogeneity in Alzheimer disease (AD) clinical progression, which could have important implications for clinical trial design and interpretation. METHODS: We applied novel reverse-time longitudinal models to analyze the trajectories of Clinical Dementia Rating Sum of Boxes (CDR-SOB) and Mini-Mental State Examination (MMSE) scores-2 common outcome measures in AD clinical trials-in 1,102 autopsy-proven AD cases (moderate/frequent neuritic plaques and Braak tangle stage III or greater) from the National Alzheimer's Coordinating Center Neuropathology database resembling participants with mild to moderate AD in therapeutic clinical trials. RESULTS: ε3/ε3 carriers (-2.43 vs -3.03 points per year). These findings remained largely unchanged after controlling for the effect of AD neuropathologic changes on the rate of cognitive decline and for the presence and severity of comorbid pathologies. CONCLUSION: genotype contributes to the heterogeneity in rate of clinical progression in AD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1212/wnl.0000000000011883

Cites

53 of 53 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Flowchart of Study Participants ADNC = Alzheimer disease neuropathological changes; CERAD = Consortium to Establish a Registry of Alzheimer’s Disease; NACC = National Alzheimer’s Coordinating Center; NP = neuritic plaque; UDS = Uniform Data Set.
Figure 1 Flowchart of Study Participants ADNC = Alzheimer disease neuropathological changes; CERAD = Consortium to Establish a Registry of Alzheimer’s Disease; NACC = National Alzheimer’s Coordinating Center; NP = neuritic plaque; UDS = Uniform Data Set.CC BY-NC-ND · PubMed Central
Figure 2 Effect of APOE Alleles on Global Functional and Cognitive Outcome Measures (CDR-SOB and MMSE) Scores (A and E) Model-based cognitive trajectories of Clinical Dementia Rating Sum of Boxes (CDR-SOB) (A) and Mini-Mental State Examination MMSE (E) scores by APOE allele groups (APOE ε3/ε3, APOE ε2, and APOE ε4 carriers) with the intercept at the time of death calculated for an 82-year-old woman with 15 years of education and autopsy findings of frequent Consortium to Establish a Registry of Alzheimer’s Disease (CERAD) neuritic plaque (NP) score and Braak neurofibrillary tangle (NFT) stage V/VI, but without adjustments for the effect of these neuropathologic variables on the rate of cognitive decline or for comorbid pathologies (model 1). (C and G) Model-based cognitive trajectories of CDR-SOB (C) and MMSE (G) scores by APOE group with the intercept at the time of death calculated for an 82-year-old woman with 15 years of education and autopsy findings of frequent CERAD NP score and Braak NFT stage V/VI and no comorbid pathologies and with adjustments for the effect of AD neuropathologic variables (CERAD and Braak) on the rate of cognitive decline and for comorbid pathologies (model 2). Note the nearly identical trajectories with and without controlling for neuropathology. (B, D, F, and H) Difference of model-based cognitive trajectories of CDR-SOB (B and D) and MMSE (F and H) scores between APOE allele groups (APOE ε2 and APOE ε4 vs APOE ε3/ε3 carriers) under models 1 (B and F) and 2 (D and H). Shaded areas represent the corresponding 95% confidence intervals.
Figure 2 Effect of APOE Alleles on Global Functional and Cognitive Outcome Measures (CDR-SOB and MMSE) Scores (A and E) Model-based cognitive trajectories of Clinical Dementia Rating Sum of Boxes (CDR-SOB) (A) and Mini-Mental State Examination MMSE (E) scores by APOE allele groups (APOE ε3/ε3, APOE ε2, and APOE ε4 carriers) with the intercept at the time of death calculated for an 82-year-old woman with 15 years of education and autopsy findings of frequent Consortium to Establish a Registry of Alzheimer’s Disease (CERAD) neuritic plaque (NP) score and Braak neurofibrillary tangle (NFT) stage V/VI, but without adjustments for the effect of these neuropathologic variables on the rate of cognitive decline or for comorbid pathologies (model 1). (C and G) Model-based cognitive trajectories of CDR-SOB (C) and MMSE (G) scores by APOE group with the intercept at the time of death calculated for an 82-year-old woman with 15 years of education and autopsy findings of frequent CERAD NP score and Braak NFT stage V/VI and no comorbid pathologies and with adjustments for the effect of AD neuropathologic variables (CERAD and Braak) on the rate of cognitive decline and for comorbid pathologies (model 2). Note the nearly identical trajectories with and without controlling for neuropathology. (B, D, F, and H) Difference of model-based cognitive trajectories of CDR-SOB (B and D) and MMSE (F and H) scores between APOE allele groups (APOE ε2 and APOE ε4 vs APOE ε3/ε3 carriers) under models 1 (B and F) and 2 (D and H). Shaded areas represent the corresponding 95% confidence intervals.CC BY-NC-ND · PubMed Central
Figure 3 Effect of APOE Alleles on Cognitive Domain–Specific Composite Measures (A, C, E, and G) Model-based cognitive trajectories of (A) memory, (C) executive, (E) attention, and (G) language composite-measures z scores by APOE allele with the intercept at the time of death calculated for an 82-year-old woman with 15 years of education and autopsy findings of frequent Consortium to Establish a Registry of Alzheimer’s Disease (CERAD) neuritic plaque score and Braak neurofibrillary tangle stage V/VI and no comorbid pathologies and with adjustments for the effect of Alzheimer disease neuropathologic variables (CERAD and Braak) on the rate of cognitive decline and for comorbid pathologies (model 2). (B, D, F, and H) Difference of model-based cognitive trajectories of (B) memory, (D) executive, (F) attention, and (H) language composite-measures z scores between APOE allele groups (APOE ε2 and APOE ε4 vs APOE ε3/ε3 carriers) under model 2. Shaded areas represent the corresponding 95% confidence intervals.
Figure 3 Effect of APOE Alleles on Cognitive Domain–Specific Composite Measures (A, C, E, and G) Model-based cognitive trajectories of (A) memory, (C) executive, (E) attention, and (G) language composite-measures z scores by APOE allele with the intercept at the time of death calculated for an 82-year-old woman with 15 years of education and autopsy findings of frequent Consortium to Establish a Registry of Alzheimer’s Disease (CERAD) neuritic plaque score and Braak neurofibrillary tangle stage V/VI and no comorbid pathologies and with adjustments for the effect of Alzheimer disease neuropathologic variables (CERAD and Braak) on the rate of cognitive decline and for comorbid pathologies (model 2). (B, D, F, and H) Difference of model-based cognitive trajectories of (B) memory, (D) executive, (F) attention, and (H) language composite-measures z scores between APOE allele groups (APOE ε2 and APOE ε4 vs APOE ε3/ε3 carriers) under model 2. Shaded areas represent the corresponding 95% confidence intervals.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 53 references

Cited by

See all 80

Metadata

Authors
Qian, J., Betensky, R. A., Hyman, B. T., & Serrano-Pozo, A.
Affiliations
  • Harvard University (US)
  • From the Department of Biostatistics and Epidemiology (J.Q.), University of Massachusetts, Amherst; New York University College of Global Public Health (R.A.B.), New York City; Department of Neurology (B.T.H., A.S.-P.), Massachusetts General Hospital, Boston; Massachusetts Alzheimer's Disease Research Center (B.T.H., A.S.-P.), Charlestown; and Harvard Medical School (B.T.H., A.S.-P.), Boston, MA.
Venue
Neurology
Published
2021-05-11
Volume
96
Issue
19
Pages
e2414-e2428
ISSN
  • 0028-3878 (ISSN-L)
  • 1526-632X
OpenAlex
W3136651487
Cited by
71
References
53
Citations by year
2026: 16 · 2025: 14 · 2024: 10 · 2023: 15 · 2022: 10 · 2021: 6
FWCI
7.35
Type
journal article
Language
en
Open access
Licence
cc-by-nc-nd
Locations
  • Neurology (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Funders
  • Alzheimer's Association (U01 AG016976, P50 AG025688, AACF-17-524184, P30 AG062421, P50 AG008702, P30 AG010133, P50 AG005146)
  • National Institutes of Health (5p30ag062428-02, AG062421, AG016976, P30 AG062428–01, AG019610, AG025688, R25-NS065743, AG013846, AG047266, AG008702)
  • National Institute on Aging (AG010133, AG 016976, P30AG053760, P30AG010129, P30AG010133, P30AG066512, AG062421, P30-AG062428, P30AG049638, P30AG028383, P30AG012300, AG 025688, P50AG005133, U01AG016976, P50AG005138, AG019610, P30AG010124, AG047266, P50AG016573, P50AG047366, P30AG008017, P30 AG062428‐01, P30AG010161, P30AG008051, R21AG053695, P50AG008702, K08AG064039, P30AG035982, AG013846, P50AG005681, P50AG005142, P50AG047270, P30AG019610, P50AG005146, P30AG013846, P50AG005136, P30AG013854, P50AG025688, P50AG047266, P30AG062429, P30AG066444, P30AG062422, P30AG062421, P50AG023501)
  • National Institute of Neurological Disorders and Stroke (R01NS094610, R25NS065743)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Clinical Neurology › Amyotrophic Lateral Sclerosis Research
Keywords
Alzheimer's disease, APOE genotype, APOE ε4, Mini-Mental State Examination, neuropathology, comorbid pathology, clinical trial design
MeSH terms
Aged, Aged, 80 and over, Alzheimer Disease, Female, Genotype, Humans, Longitudinal Studies, Male, Cohort Studies, Disease Progression, Apolipoprotein E3, Apolipoprotein E4, Apolipoprotein E2, Cognitive Dysfunction

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Association of APOE Genotype With Heterogeneity of Cognitive Decline Rate in Alzheimer Disease. https://app.cochat.ai/papers/10.1212/wnl.0000000000011883
The paper
Qian, J., Betensky, R. A., Hyman, B. T., & Serrano-Pozo, A. (2021). Association of APOE Genotype With Heterogeneity of Cognitive Decline Rate in Alzheimer Disease. Neurology. https://doi.org/10.1212/wnl.0000000000011883

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.